Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results

18-05-2014 EurekAlert!Comments (0)

BiotechnologyGreeceSpironolactone

Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas. The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

Read more on EurekAlert!

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top